Vagus-hermostimulaatio kohtalaiseen tai vaikeaan nivelreumaan (RESET-RA)
Vagus-hermostimulaatio SetPoint-järjestelmän avulla keskivaikeaan tai vaikeaan nivelreumaan: RESET-RA-tutkimus
The RESET-RA study will assess the safety and efficacy of the SetPoint System (study device) for the treatment of adult patients with active, moderate to severe rheumatoid arthritis who have had an inadequate response or intolerance to biologic or targeted synthetic Disease-Modifying Anti-Rheumatic Drugs (DMARDs). The study device contains a miniaturized stimulator (implant) that is surgically placed under general anesthesia on the vagus nerve through a small incision on the left side of the neck (implant procedure). The study will enroll up to 250 subjects at up to 45 sites. All eligible subjects will undergo the implant procedure. Half of the subjects will receive active stimulation (treatment) and the other half will receive non-active stimulation (control). After completing primary endpoint assessments at Week 12, there will be a one-way crossover of control subjects to active stimulation and a 252-week open-label follow-up with all subjects (treatment and control) receiving active stimulation to evaluate long-term safety.
Tutkimuksen yleiskatsaus
Tila
Tila
Ehdot
Ehdot
Interventio / Hoito
Interventio / Hoito
Yksityiskohtainen kuvaus
The RESET-RA study is an operationally seamless, 2-stage, randomized, double-blind, sham-controlled, multicenter pivotal study enrolling up to 250 subjects at up to 45 study centers across the U.S. The study will assess the safety and efficacy of the SetPoint System (study device) for the treatment of adult patients with active, moderate to severe rheumatoid arthritis (RA) who have had an inadequate response, loss of response or intolerance to biologic or targeted synthetic Disease-Modifying Anti-Rheumatic Drugs (DMARDs). The study device contains a miniaturized stimulator (implant) that is surgically implanted inside the left side of the neck on the vagus nerve (implant procedure). The implant delivers a small amount of electricity (stimulation) to the nerve. All eligible subjects will undergo the surgery under general anesthesia. Half of the subjects will receive active stimulation (the treatment group) and the other half will receive non-active stimulation (the control group). Stimulation will be delivered for 1 min once per day for 12 weeks. After completing primary endpoint assessments at Week 12, there will be a one-way crossover of control subjects to active stimulation and a 252-week open-label follow-up with all subjects (treatment and control) receiving active stimulation to evaluate long-term safety. Blinding will be maintained until the last enrolled and randomized subject in Stage 2 completes Week 12 assessments, and the study database is locked.
Opintotyyppi
Opintotyyppi
Ilmoittautuminen (Todellinen)
Ilmoittautuminen
Vaihe
Vaihe
- Vaihe 3
Yhteystiedot ja paikat
Opiskelupaikat
-
-
Arizona
-
Mesa, Arizona, Yhdysvallat, 85210
- Arizona Arthritis ans Rheumatology Research, PPLC
-
Phoenix, Arizona, Yhdysvallat, 85037
- Arizona Arthritis Rheumatology & Research, PLLC
-
Tucson, Arizona, Yhdysvallat, 85704
- Arizona Arthritis & Rheumatology Research, PLLC
-
-
California
-
Covina, California, Yhdysvallat, 91722
- Medvin Clinical Research
-
Upland, California, Yhdysvallat, 91786
- Inland Rheumatology Clinical Trials
-
Whittier, California, Yhdysvallat, 90602
- Medvin Clinical Research
-
-
Colorado
-
Fort Collins, Colorado, Yhdysvallat, 80528
- The Arthritis & Rheumatology Clinic of Northern Colorado
-
-
Connecticut
-
Stamford, Connecticut, Yhdysvallat, 06905
- Stamford Therapeutics Consortium
-
-
Delaware
-
Lewes, Delaware, Yhdysvallat, 19958
- Delaware Arthritis
-
-
Florida
-
Aventura, Florida, Yhdysvallat, 33180
- Arthritis & Rheumatic Disease Specialties
-
Avon Park, Florida, Yhdysvallat, 33825
- HARAC Research Corporation
-
Boynton Beach, Florida, Yhdysvallat, 33472
- RecioMed Clinical Research Network, Inc.
-
Clearwater, Florida, Yhdysvallat, 33765
- Bay Area Rheumatology
-
Plantation, Florida, Yhdysvallat, 33324
- IRIS Research and Development
-
-
Georgia
-
Augusta, Georgia, Yhdysvallat, 30912
- Augusta University
-
Lawrenceville, Georgia, Yhdysvallat, 30044
- Parris and Associates Rheumatology
-
-
Illinois
-
Chicago, Illinois, Yhdysvallat, 60611
- Northwestern University
-
Willowbrook, Illinois, Yhdysvallat, 60527
- Willow Rheumatology and Wellness PLLC
-
-
Massachusetts
-
Boston, Massachusetts, Yhdysvallat, 02114
- Massachusetts General Hospital Division of Rheumatology, Allergy, and Immunology
-
-
Michigan
-
Lansing, Michigan, Yhdysvallat, 48910
- June DO, PC
-
-
Minnesota
-
Eagan, Minnesota, Yhdysvallat, 55121
- Saint Paul Rheumatology, P.A.
-
-
Missouri
-
Kansas City, Missouri, Yhdysvallat, 64151
- Kansas City Physician Partners
-
St Louis, Missouri, Yhdysvallat, 63122
- West County Rheumatology
-
-
Nebraska
-
Lincoln, Nebraska, Yhdysvallat, 68516
- Physician Research Collaboration, LLC
-
-
New Mexico
-
Albuquerque, New Mexico, Yhdysvallat, 87102
- Albuquerque Center for Rheumatology
-
-
New York
-
Babylon, New York, Yhdysvallat, 11702
- Long Island Regional Arthritis & Osteoporosis Care
-
-
North Carolina
-
Charleston, North Carolina, Yhdysvallat, 28202
- Arthritis & Osteoporosis Consultants Of The Carolinas
-
Charlotte, North Carolina, Yhdysvallat, 28210
- DJL Clinical Research
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Yhdysvallat, 73103
- Health Research of Oklahoma, PLLC
-
Oklahoma City, Oklahoma, Yhdysvallat, 73116
- Rheumatology Associates of Oklahoma
-
-
Pennsylvania
-
Allentown, Pennsylvania, Yhdysvallat, 18103
- Lehigh Valley Health Network
-
Philadelphia, Pennsylvania, Yhdysvallat, 19104
- University of Pennsylvania Medical Center
-
-
Texas
-
Allen, Texas, Yhdysvallat, 75013
- Arthritis & Rheumatology Research Institute, PLLC
-
Austin, Texas, Yhdysvallat, 78745
- Tekton Research
-
Austin, Texas, Yhdysvallat, 78717
- Austin Regional Clinic
-
Austin, Texas, Yhdysvallat, 78746
- Central Texas Rheumatology Associates
-
Colleyville, Texas, Yhdysvallat, 76034
- Precision Comprehensive Clinical Research Solutions
-
Houston, Texas, Yhdysvallat, 77043
- Biopharma Informatic
-
Mesquite, Texas, Yhdysvallat, 75150
- Southwest Rheumatology Research LLC
-
San Antonio, Texas, Yhdysvallat, 78229
- Clinical Trials of Texas, Inc
-
-
Virginia
-
Fairfax, Virginia, Yhdysvallat, 22033
- Annapolis Rheumatology
-
-
Washington
-
Bothell, Washington, Yhdysvallat, 98021
- Sound Clinical Research, LLC
-
-
West Virginia
-
Morgantown, West Virginia, Yhdysvallat, 26506
- West Virginia University
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- 22-75 years of age at screening
- Active moderate or severe RA, defined as at least 4/28 tender and 4/28 swollen joints
- Demonstrated an inadequate response, loss of response, or intolerance to 1 or more approved for rheumatoid arthritis biologic or targeted synthetic Disease-Modifying Anti-Rheumatic Drugs (DMARDs), including Janus kinase inhibitors (JAKi)
- Receiving treatment with at least 1 conventional synthetic DMARD for at least 12 weeks and on a continuous non-changing dose and route of administration for at least 4 weeks prior to Screening and able to continue the same stable dose through Week 12
Exclusion Criteria:
- Untreated or poorly controlled psychiatric illness or history of substance abuse
- Significant immunodeficiency due to underlying illness
- History of stroke or transient ischemic attack, or diagnosis of cerebrovascular fibromuscular dysplasia
- Clinically significant cardiovascular disease
- Neurological syndromes, including multiple sclerosis, Alzheimer's disease, or Parkinson's disease
- Uncontrolled fibromyalgia
- History of left or right carotid surgery
- History of unilateral or bilateral vagotomy, partial or complete splenectomy
- Recurrent vasovagal syncope episodes
- Current, regular use of tobacco products
- Hypersensitivity/allergy to MRI contrast agents and/or unable to perform MRI
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Nelinkertaistaa
Aseiden lukumäärä
Aseet ja interventiot
Osallistujaryhmä / ArmOsallistujaryhmä / Arm |
Interventio / HoitoInterventio / Hoito |
|---|---|
|
Kokeellinen: Treatment
Active stimulation for 1 min once per day |
The SetPoint System (study device) contains a miniaturized stimulator (implant) that is surgically implanted inside the left side of the neck on the vagus nerve (implant procedure). All eligible subjects will undergo the surgery under general anesthesia in outpatient settings.
Muut nimet:
All subjects will continue to take at least one type of conventional synthetic DMARD at the same stable dose as for 4 weeks prior to consent
Muut nimet:
Active stimulation for 1 min once per day |
|
Huijausvertailija: Control
Non-active stimulation for 1 min once per day |
The SetPoint System (study device) contains a miniaturized stimulator (implant) that is surgically implanted inside the left side of the neck on the vagus nerve (implant procedure). All eligible subjects will undergo the surgery under general anesthesia in outpatient settings.
Muut nimet:
All subjects will continue to take at least one type of conventional synthetic DMARD at the same stable dose as for 4 weeks prior to consent
Muut nimet:
Non-active stimulation for 1 min once per day |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
the American College of Rheumatology (ACR) 20 Response
Aikaikkuna: Week 12
|
Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L). |
Week 12
|
Toissijaiset tulostoimenpiteet
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
DAS28-CRP Good or Moderate Response as Defined by European League Against Rheumatism (EULAR)
Aikaikkuna: Week 12
|
The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) good or moderate response as defined by EULAR based on a composite score of 4 items: tender and swollen joint counts of 28 joints (scale 0=best to 28=worst), subject global assessment (0=best to 10=worst) and high-sensitivity C-reactive protein (hsCRP) concentration (mg/L). A total score ranges from 0 to 10 and is computed as follows: DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96 A subject is considered having a moderate treatment response if:
A subject is considered having a good treatment response if: • DAS28-CRP score improvement from baseline to Week 12 is > 1.2 and the DAS28-CRP score at Week 12 is ≤ 3.2 |
Week 12
|
|
DAS28-CRP Response (MCID -1.2) at Week 12
Aikaikkuna: Week 12
|
The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) response is based on the minimal clinically important difference (MCID) of -1.2 from baseline. DAS28-CRP is based on a composite score of 4 items: tender and swollen joint counts of 28 joints (scale 0=best to 28=worst), subject global assessment (0=best to 10=worst) and high-sensitivity C-reactive protein (hsCRP) concentration (mg/L). A total score ranges from 0 to 10 and is computed as follows: DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96 |
Week 12
|
|
Health Assessment Questionnaire Disability Index (HAQ-DI) Response (MCID -0.22)
Aikaikkuna: Week 12
|
HAQ-DI response based on the MCID of -0.22 from baseline. The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:
Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:
|
Week 12
|
|
ACR20 Response at Week 12 From Day 0
Aikaikkuna: Week 12
|
Response is defined as achieving at least 20% improvement from Day 0 to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worse), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/mL). |
Week 12
|
Muut tulostoimenpiteet
Muut tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Bone Erosion Progression, All Completers
Aikaikkuna: Week 12
|
RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand. A total score for each pathology is generated by the summation of individual joint/bone scores as follows:
The proportion of bone erosion progressors is the % subjects with an increase of > 0.5 on the bone erosion score, comparing baseline to Week 12. An increase of > 0.5 represents disease progression. |
Week 12
|
|
Bone Erosion Progression, All Completers With Erosive Phenotype
Aikaikkuna: Week 12
|
RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand. A total score for each pathology is generated by the summation of individual joint/bone scores as follows:
The proportion of bone erosion progressors is the % subjects with an increase of > 0.5 on the bone erosion score, comparing baseline to Week 12. An increase of > 0.5 represents disease progression. |
Week 12
|
|
Bone Erosion Progression, All Completers That Previously Only Failed 1 b/tsDMARD
Aikaikkuna: Week 12
|
RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand. A total score for each pathology is generated by the summation of individual joint/bone scores as follows:
The proportion of bone erosion progressors is the % subjects with an increase of > 0.5 on the bone erosion score, comparing baseline to Week 12. An increase of > 0.5 represents disease progression. |
Week 12
|
|
Change in Erosion Score, All Completers
Aikaikkuna: Week 12
|
RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores: • Bone erosion: 25 bones each scored on a scale from 0 (0-10% eroded volume) to 10 (91-100% eroded volume), resulting in a total score from 0 to 250. |
Week 12
|
|
Change in Erosion Score, All Completers With Erosive Phenotype
Aikaikkuna: Week 12
|
RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores: • Bone erosion: 25 bones each scored on a scale from 0 (0-10% eroded volume) to 10 (91-100% eroded volume), resulting in a total score from 0 to 250. |
Week 12
|
|
Change in Erosion Score, All Completers That Previously Only Failed 1 b/tsDMARD
Aikaikkuna: Week 12
|
RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores: • Bone erosion: 25 bones each scored on a scale from 0 (0-10% eroded volume) to 10 (91-100% eroded volume), resulting in a total score from 0 to 250. |
Week 12
|
|
Change in Synovitis Score, All Completers
Aikaikkuna: Week 12
|
RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores: • Synovitis: 8 joints each scored on a scale from 0 = normal to 3 = severe, resulting in a total score from 0 to 24. |
Week 12
|
|
Change in Synovitis Score, All Completers With Erosive Phenotype
Aikaikkuna: Week 12
|
RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores: • Synovitis: 8 joints each scored on a scale from 0 = normal to 3 = severe, resulting in a total score from 0 to 24. |
Week 12
|
|
Change in Synovitis Score, All Completers That Previously Only Failed 1 b/tsDMARD
Aikaikkuna: Week 12
|
RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores: • Synovitis: 8 joints each scored on a scale from 0 = normal to 3 = severe, resulting in a total score from 0 to 24. |
Week 12
|
|
Change in Osteitis Score, All Completers
Aikaikkuna: Week 12
|
RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores: • Osteitis: 25 bones scored on a scale from 0 (no osteitis) to 3 (68-100% of bone volume involved), resulting in a total score from 0 to 75. |
Week 12
|
|
Change in Osteitis Score, All Completers With Erosive Phenotype
Aikaikkuna: Week 12
|
RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores: • Osteitis: 25 bones scored on a scale from 0 (no osteitis) to 3 (68-100% of bone volume involved), resulting in a total score from 0 to 75. |
Week 12
|
|
Change in Osteitis Score, All Completers That Previously Only Failed 1 b/tsDMARD
Aikaikkuna: Week 12
|
RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores: • Osteitis: 25 bones scored on a scale from 0 (no osteitis) to 3 (68-100% of bone volume involved), resulting in a total score from 0 to 75. |
Week 12
|
|
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission
Aikaikkuna: Week 12
|
The CDAI score is based on 4 items:
The CDAI score is calculated as follows and ranges from 0 to 76: • CDAI = TJC28 + SJC28 + SGA + EGA The CDAI score corresponds to the current RA activity:
|
Week 12
|
|
DAS28-CRP Low Disease Activity (LDA) or Remission
Aikaikkuna: Week 12
|
The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:
A total score ranges from 0 to 10 and is computed as follows: DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96 The DAS28-CRP score corresponds to the current RA activity:
|
Week 12
|
|
the American College of Rheumatology (ACR) 20 Response, All Completers
Aikaikkuna: Week 24
|
Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L). |
Week 24
|
|
the American College of Rheumatology (ACR) 20 Response, Non-augmented
Aikaikkuna: Week 24
|
Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L). |
Week 24
|
|
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission, All Completers
Aikaikkuna: Week 24
|
The CDAI score is based on 4 items:
The CDAI score is calculated as follows and ranges from 0 to 76: • CDAI = TJC28 + SJC28 + SGA + EGA The CDAI score corresponds to the current RA activity:
|
Week 24
|
|
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission, Non-augmented
Aikaikkuna: Week 24
|
The CDAI score is based on 4 items:
The CDAI score is calculated as follows and ranges from 0 to 76: • CDAI = TJC28 + SJC28 + SGA + EGA The CDAI score corresponds to the current RA activity:
|
Week 24
|
|
DAS28-CRP Low Disease Activity (LDA) or Remission, All Completers
Aikaikkuna: Week 24
|
The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:
A total score ranges from 0 to 10 and is computed as follows: DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96 The DAS28-CRP score corresponds to the current RA activity:
|
Week 24
|
|
DAS28-CRP Low Disease Activity (LDA) or Remission, Non-augmented
Aikaikkuna: Week 24
|
The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:
A total score ranges from 0 to 10 and is computed as follows: DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96 The DAS28-CRP score corresponds to the current RA activity:
|
Week 24
|
|
Health Assessment Questionnaire Disability Index (HAQ-DI) MCID Response, All Completers
Aikaikkuna: Week 24
|
HAQ-DI response based on the MCID of -0.22 from baseline. The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:
Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:
|
Week 24
|
|
Health Assessment Questionnaire Disability Index (HAQ-DI) Response (MCID -0.22), Non-augmented
Aikaikkuna: Week 24
|
HAQ-DI response based on the MCID of -0.22 from baseline. The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:
Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:
|
Week 24
|
|
Study Participants That Are Somewhat to Very Satisfied With the SetPoint System for Treatment of Rheumatoid Arthritis
Aikaikkuna: Week 24
|
Patient satisfaction was assessed at Week 24 using five-point Likert rating scale:
|
Week 24
|
|
Study Participants That Are Neither Satisfied Nor Dissatisfied With the SetPoint System for Treatment of Rheumatoid Arthritis
Aikaikkuna: Week 24
|
Patient satisfaction was assessed at Week 24 using five-point Likert rating scale:
|
Week 24
|
|
Study Participants That Are Somewhat to Very Dissatisfied With the SetPoint System for Treatment of Rheumatoid Arthritis
Aikaikkuna: Week 24
|
Patient satisfaction was assessed at Week 24 using five-point Likert rating scale:
|
Week 24
|
|
Study Participants That Would Recommend the SetPoint System to a Family Member or Friend
Aikaikkuna: Week 24
|
Patients were asked a question about whether they would recommend the SetPoint System to family and friends |
Week 24
|
|
the American College of Rheumatology (ACR) 20 Response, All Completers
Aikaikkuna: Week 36
|
Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L). |
Week 36
|
|
the American College of Rheumatology (ACR) 20 Response, Non-augmented
Aikaikkuna: Week 36
|
Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L). |
Week 36
|
|
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission, All Completers
Aikaikkuna: Week 36
|
The CDAI score is based on 4 items:
The CDAI score is calculated as follows and ranges from 0 to 76: • CDAI = TJC28 + SJC28 + SGA + EGA The CDAI score corresponds to the current RA activity:
|
Week 36
|
|
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission, Non-augmented
Aikaikkuna: Week 36
|
The CDAI score is based on 4 items:
The CDAI score is calculated as follows and ranges from 0 to 76: • CDAI = TJC28 + SJC28 + SGA + EGA The CDAI score corresponds to the current RA activity:
|
Week 36
|
|
DAS28-CRP Low Disease Activity (LDA) or Remission, All Completers
Aikaikkuna: Week 36
|
The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:
A total score ranges from 0 to 10 and is computed as follows: DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96 The DAS28-CRP score corresponds to the current RA activity:
|
Week 36
|
|
DAS28-CRP Low Disease Activity (LDA) or Remission, Non-augmented
Aikaikkuna: Week 36
|
The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:
A total score ranges from 0 to 10 and is computed as follows: DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96 The DAS28-CRP score corresponds to the current RA activity:
|
Week 36
|
|
Health Assessment Questionnaire Disability Index (HAQ-DI) MCID Response, All Completers
Aikaikkuna: Week 36
|
HAQ-DI response based on the MCID of -0.22 from baseline. The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:
Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:
|
Week 36
|
|
Health Assessment Questionnaire Disability Index (HAQ-DI) Response (MCID -0.22), Non-augmented
Aikaikkuna: Week 36
|
HAQ-DI response based on the MCID of -0.22 from baseline. The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:
Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:
|
Week 36
|
|
the American College of Rheumatology (ACR) 20 Response, All Completers
Aikaikkuna: Week 48
|
Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L). |
Week 48
|
|
the American College of Rheumatology (ACR) 20 Response, Non-augmented
Aikaikkuna: Week 48
|
Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L). |
Week 48
|
|
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission, All Completers
Aikaikkuna: Week 48
|
The CDAI score is based on 4 items:
The CDAI score is calculated as follows and ranges from 0 to 76: • CDAI = TJC28 + SJC28 + SGA + EGA The CDAI score corresponds to the current RA activity:
|
Week 48
|
|
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission, Non-augmented
Aikaikkuna: Week 48
|
The CDAI score is based on 4 items:
The CDAI score is calculated as follows and ranges from 0 to 76: • CDAI = TJC28 + SJC28 + SGA + EGA The CDAI score corresponds to the current RA activity:
|
Week 48
|
|
DAS28-CRP Low Disease Activity (LDA) or Remission, All Completers
Aikaikkuna: Week 48
|
The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:
A total score ranges from 0 to 10 and is computed as follows: DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96 The DAS28-CRP score corresponds to the current RA activity:
|
Week 48
|
|
DAS28-CRP Low Disease Activity (LDA) or Remission, Non-augmented
Aikaikkuna: Week 48
|
The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:
A total score ranges from 0 to 10 and is computed as follows: DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96 The DAS28-CRP score corresponds to the current RA activity:
|
Week 48
|
|
Health Assessment Questionnaire Disability Index (HAQ-DI) MCID Response, All Completers
Aikaikkuna: Week 48
|
HAQ-DI response based on the MCID of -0.22 from baseline. The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:
Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:
|
Week 48
|
|
Health Assessment Questionnaire Disability Index (HAQ-DI) Response (MCID -0.22), Non-augmented
Aikaikkuna: Week 48
|
HAQ-DI response based on the MCID of -0.22 from baseline. The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:
Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:
|
Week 48
|
|
the American College of Rheumatology (ACR) 20 Response, Subjects With 1 Prior b/tsDMARD
Aikaikkuna: Week 12
|
Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L). |
Week 12
|
|
the American College of Rheumatology (ACR) 20 Response, Subjects With 2 Prior b/tsDMARD
Aikaikkuna: Week 12
|
Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L). |
Week 12
|
|
the American College of Rheumatology (ACR) 20 Response, Subjects With 3 Prior b/tsDMARD
Aikaikkuna: Week 12
|
Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L). |
Week 12
|
|
the American College of Rheumatology (ACR) 20 Response, Subjects With >=4 Prior b/tsDMARD
Aikaikkuna: Week 12
|
Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L). |
Week 12
|
Yhteistyökumppanit ja tutkijat
Sponsori
Sponsori
Tutkijat
Tutkijat
- Päätutkija: Mark Richardson, MD PhD, Massachusetts General Hospital
- Päätutkija: John Tesser, MD, Arizona Arthritis and Rheumatology Research, P.C.
Julkaisuja ja hyödyllisiä linkkejä
Yleiset julkaisut
- Peterson D, Van Poppel M, Boling W, Santos P, Schwalb J, Eisenberg H, Mehta A, Spader H, Botros J, Vrionis FD, Ko A, Adelson PD, Lega B, Konrad P, Calle G, Vale FL, Bucholz R, Richardson RM. Clinical safety and feasibility of a novel implantable neuroimmune modulation device for the treatment of rheumatoid arthritis: initial results from the randomized, double-blind, sham-controlled RESET-RA study. Bioelectron Med. 2024 Mar 13;10(1):8. doi: 10.1186/s42234-023-00138-x.
- Tesser JRP, Crowley AR, Box EJ, June JP, Wickersham PB, Valenzuela GJ, Gaylis NB, Lam GKW, Pacheco LA, Ridley DJ, Pinto-Patarroyo GP, Novack SN, Churchill MA, Kohler M, Lee EC, Pando JA, Parris GR, Peterson JR, Shah T, Singhal AK, Vuong V, Levine YA, Evangelista ML, Derosier AA, Curtis JR, Richardson RM, Chernoff D. Vagus nerve-mediated neuroimmune modulation for rheumatoid arthritis: a pivotal randomized controlled trial. Nat Med. 2026 Jan;32(1):369-378. doi: 10.1038/s41591-025-04114-7. Epub 2025 Dec 22.
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Opiskelun aloitus
Ensisijainen valmistuminen (Todellinen)
Ensisijainen valmistuminen
Opintojen valmistuminen (Arvioitu)
Opintojen valmistuminen
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Ensimmäinen Lähetetty
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin päivitys julkaistu
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
Muut tutkimustunnusnumerot
- SPM-020
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
No sharing data is planned.
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .